Lupus Trials / Trials in New York
35 Recruiting Trials

Clinical Trials
for Lupus in New York

35 clinical trials for Lupus are currently recruiting participants at study sites in New York. Study-related care is provided at no cost.

35
Recruiting trials
53
Study sites
16
Cities
20
Industry-sponsored
14
Phase 2
5
Phase 3

Lupus clinical trials in New York: what to expect

Lupus trials are mostly for systemic lupus that stays active despite standard treatment. They test biologic infusions and injections that target the immune signals behind lupus, new oral medicines, and treatments that reduce the need for steroids. Lupus nephritis, where the disease affects the kidneys, has its own trials with their own entry rules, and cell-based therapies are beginning to be tested in people whose lupus has not responded to anything else.

In New York, recruiting lupus studies are concentrated in New York, Syracuse, Manhasset and Rochester, with sites in 12 other cities. 20 of the 35 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who lupus trials usually look for

Trials require a confirmed diagnosis with positive antibody tests, active disease above a threshold on a standard activity score at screening, and a stable regimen of your current medicines (an antimalarial, an immunosuppressant, a steroid below a stated dose) for several weeks beforehand. Lupus nephritis trials need a recent kidney biopsy and a protein-in-urine level above a cut-off. Common exclusions are severe active lupus of the brain, a recent biologic, serious infection and pregnancy. Ages are usually 18 to 75.

What taking part involves

Screening includes blood and urine tests and a review of your records. Most trials then last a year with visits every four weeks for an infusion or injection, lab monitoring and a disease-activity exam, often with a plan to taper steroids. The study drug is usually compared with placebo, both added to your existing treatment, and flares are treated as needed. An open-label extension generally follows. All study care is free and visits are usually paid.

Questions worth asking the study team

Whether your current medicines stay unchanged; how the steroid taper works; the chance of placebo and whether an extension follows; what happens during a flare; and what the trial means for pregnancy planning.

Showing 20 of 35 recruiting Lupus trials in New York

Safety and Efficacy of ONT01 in Lupus
EARLY_PHASE1 New York, New York NCT07107659
This trial is looking for adults with lupus nephritis or systemic lupus erythematosus. Participants will take a medication called ONT01 and will be monitored for safety and effects on their condition.
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
PHASE3 Avondale, Arizona +4 sites NCT06617325
This trial is looking for people aged 16 and older who have moderate to severe systemic lupus erythematosus (SLE) and are not getting enough improvement from their current medications. Participants will receive dapirolizumab pegol as an additional treatment along with their existing medications.
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
PHASE3 Orchard Park, New York +4 sites NCT06711887
This trial is looking for people who have lupus nephritis and participated in a previous study. Participants will either continue treatment with ianalumab or stop treatment to see how they respond over time.
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
PHASE3 Phoenix, Arizona +4 sites NCT05835310
This trial is looking for children with moderate to severe systemic lupus erythematosus (SLE) to test a treatment called Anifrolumab. Participants will be monitored to understand how well the treatment works and its safety.
Recruiting
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
PHASE3 New York, New York +4 sites NCT05799378
This trial is looking for older adults with lupus who want to see if they can safely stop taking hydroxychloroquine. Participants will be monitored for one year to check their disease activity.
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
PHASE2 Loma Linda, California +4 sites NCT05039619
This trial is looking for teenagers aged 12 to 18 and children aged 5 to under 12 who have been diagnosed with lupus nephritis. Participants will receive treatment with obinutuzumab and be monitored for safety and effectiveness.
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
PHASE1 Orange, California +4 sites NCT06121297
This trial is looking for adults with active systemic lupus erythematosus or lupus nephritis. Participants will receive the treatment CABA-201 and will be monitored for safety and effectiveness.
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
PHASE2 Beverly Hills, California +4 sites NCT07260877
This trial is looking for adults with cutaneous lupus who may also have systemic lupus. Participants will take the study drug VENT-03 or a placebo for a total of 12 weeks and visit the clinic monthly for checkups.
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
PHASE2 Phoenix, Arizona +4 sites NCT05268289
This trial is looking for people with active lupus nephritis. Participants will take a medication called LNP023 along with their usual treatment to see how well it works and how safe it is.
Recruiting
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
PHASE2 Hawthorne, New York +3 sites NCT07328581
This trial is looking for people aged 16-70 who have systemic lupus erythematosus that hasn't responded to treatment. Participants will receive a special infusion after a preparatory treatment to help their condition.
Recruiting
VIBRANT: VIB4920 for Active Lupus Nephritis
PHASE2 La Jolla, California +4 sites NCT05201469
This trial is looking for adults with active lupus nephritis. Participants will take VIB4920 along with other medications to see if it helps improve kidney function.
Recruiting
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
PHASE2 San Francisco, California +4 sites NCT05538208
This trial is looking for young people aged 8 to 20 with lupus nephritis. Participants will take a medication called Mycophenolate Mofetil and visit the study site regularly for assessments.
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
PHASE1 San Francisco, California +4 sites NCT06897930
This trial is looking for adults aged 18 to 70 who have severe systemic lupus erythematosus that hasn’t improved with other treatments. Participants will receive a special therapy called AZD0120 and will be monitored for its safety and effectiveness.
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
PHASE2 New York, New York +4 sites NCT07053800
This trial is looking for people aged 12 to 65 with severe lupus that is hard to treat and causing kidney problems. Participation involves receiving a single treatment of a drug called obe-cel after a procedure to prepare the body.
Recruiting
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
PHASE1 Syracuse, New York +4 sites NCT06625671
This trial is looking for healthy adults and adults with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE) to participate in a study of a new treatment called DB-2304. Participants will need to complete certain tests and follow study guidelines.
Recruiting
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
PHASE4 New York, New York +3 sites NCT06875960
This trial is looking for people who have lupus and want to continue their treatment with Deucravacitinib. To join, you need to have finished certain previous studies and be assessed by a doctor to see if you can benefit from further treatment.
Recruiting
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
PHASE4 La Mesa, California +4 sites NCT07611214
This trial is looking for adults with lupus nephritis who want to test a new combination treatment. Participants will need to take some specific medications and be within a certain age range.
Recruiting
Trial of Belimumab in Early Lupus
PHASE4 Manhasset, New York NCT03543839
Recruiting
Safety of the Herpes Zoster Subunit Vaccine in Lupus
PHASE4 New York, New York +1 sites NCT05559671
This trial is looking for adults with Systemic Lupus Erythematosus who are interested in participating in a study about a herpes vaccine. Participants will receive either the herpes vaccine or a placebo and will be monitored for safety and immune response.
Recruiting
Alnuctamab for Refractory SLE (LATTE Study)
PHASE1 New York, New York NCT07219563
This trial is looking for adults with moderate to severe systemic lupus erythematosus that hasn't responded to standard medications. Participants will receive a new treatment called alnuctamab to see how safe and effective it is.
Recruiting
See all 35 Lupus trials in New York

Where the Lupus studies are in New York

Research sites running the most studies
  • Hospital for Special Surgery, New York5 trials
  • Columbia University Medical Center, New York4 trials
  • Icahn School of Medicine at Mount Sinai, New York3 trials
  • NYU Langone Health, New York3 trials
  • Research Site, New York3 trials
  • University of Rochester Medical Center, Rochester2 trials
By city

Counts are recruiting studies listing at least one site in New York, from ClinicalTrials.gov, refreshed every two days.

Lupus clinical trials in New York: common questions

How many Lupus clinical trials are recruiting in New York?
TrialFinder currently lists 35 recruiting Lupus clinical trials with study sites in New York. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Lupus clinical trials located in New York?
Study sites for the Lupus trials listed on this page include New York, Orchard Park, Hawthorne, Syracuse, Manhasset. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Lupus clinical trial in New York?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Lupus trials in New York also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Lupus clinical trial in New York?
Each study sets its own criteria based on age, Lupus diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will my regular lupus medicines stop if I join a trial?
No. Lupus trials add the study treatment to a stable regimen of your current medicines. Many include a planned steroid taper as one of the goals, managed by the study doctor.
Is there a placebo in lupus trials?
Usually, but always on top of standard treatment, never instead of it, and most trials move everyone onto the active drug in an extension after the main study period.
Can I join a trial if I have lupus nephritis?
Yes. Lupus nephritis has dedicated trials that require a recent kidney biopsy and a stated level of protein in the urine. General lupus trials often exclude active nephritis, so look for the ones that name it.
Lupus Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Lupus trials near you in New York.

Get Matched — Free
No insurance required
About Lupus Trials

Lupus trials evaluate belimumab, anifrolumab, JAK inhibitors, and other biologics targeting the immune dysregulation behind systemic lupus erythematosus.

All Lupus trials →
Other Conditions in New York
Diabetes Cancer Breast Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in New York →